Page last updated: 2024-10-28

guanfacine and Attention Deficit and Disruptive Behavior Disorders

guanfacine has been researched along with Attention Deficit and Disruptive Behavior Disorders in 9 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Attention Deficit and Disruptive Behavior Disorders: Includes two similar disorders: oppositional defiant disorder and CONDUCT DISORDERS. Symptoms occurring in children with these disorders include: defiance of authority figures, angry outbursts, and other antisocial behaviors.

Research Excerpts

Excerpt	Relevance	Reference
"Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs."	2.75	Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. ( Connor, DF; Findling, RL; Kollins, SH; López, FA; Lyne, A; Sallee, F; Tremblay, G, 2010)
" The mechanism of this proposed interaction may involve drug-drug competition at the level of hepatic glucuronidation (conjugation), although shifts in protein binding cannot be ruled out."	2.69	Increased plasma valproate concentrations when coadministered with guanfacine. ( Ambrosini, PJ; Sheikh, RM, 1998)

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (22.22)	18.2507
2000's	1 (11.11)	29.6817
2010's	5 (55.56)	24.3611
2020's	1 (11.11)	2.80

Authors

Authors	Studies
Newcorn, JH	2
Huss, M	1
Connor, DF	2
Hervás, A	1
Werner-Kiechle, T	1
Robertson, B	1
Luber, MJ	1
Coffey, BJ	1
Gamms, SH	1
Findling, RL	2
McBurnett, K	1
White, C	1
Youcha, S	1
Stahl, SM	1
Kollins, SH	1
Sallee, F	1
López, FA	1
Lyne, A	1
Tremblay, G	1
Signorovitch, J	1
Erder, MH	1
Xie, J	1
Sikirica, V	1
Lu, M	1
Hodgkins, PS	1
Wu, EQ	1
Jentsch, JD	1
Ambrosini, PJ	1
Sheikh, RM	1
Schulz, K	1
Harrison, M	1
DeBellis, MD	1
Udarbe, JK	1
Halperin, JM	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 (Guanfacine Hydrochloride) in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention Deficit/Hyperactivity Disorder[NCT00367835]			Phase 3	217 participants (Actual)	Interventional	2006-12-04	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at Up to 8 Weeks

The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	Units on a scale (Mean)
SPD503	-23.8
Placebo	-11.4

Change From Baseline in Diastolic Blood Pressure at Up to 8 Weeks

(NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	mmHg (Mean)
SPD503	-1.3
Placebo	0.9

Change From Baseline in Electrocardiogram Results (QTcF Interval) at Up to 8 Weeks

QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate (e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation. (NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	msec (Mean)
SPD503	5.2
Placebo	2.1

Change From Baseline in Pulse Rate at Up to 8 Weeks

(NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	beats/min (Mean)
SPD503	-4.3
Placebo	0.7

Change From Baseline in Systolic Blood Pressure at Up to 8 Weeks

(NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	mmHg (Mean)
SPD503	-2.6
Placebo	0.7

Change From Baseline in the 40-Item Conduct Problem Scale of the New York Parent's Rating Scale-School-aged (NYPRS-S) Score at Up to 8 Weeks

Each item on the NYPRS-S is scored from a range of 0 (not at all) to 3 (very much) with total scores ranging from 0 to 120. Higher scores are reflective of increased disease severity. (NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	units on a scale (Mean)
SPD503	-15.6
Placebo	-10.3

Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Up to 8 Weeks

The oppositional subscale of the CPRS-R:L contains 10 items designed to reflect criteria for oppositional defiance disorder (ODD). Each item is scored on a range from 0 (not true at all) to 3 (very much true) with total scores ranging from 0 to 30. Higher scores are reflective of more severe symptoms. (NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	Units on a scale (Mean)
SPD503	-10.8
Placebo	-7.0

Change From Baseline in the Parent Stress Index-Short Form (PSI/SF) Score at Up to 8 Weeks

The response to each of the 36 items on the PSI/SF is converted to a five-point scale from 1 (strongly agree) to 5 (strongly disagree) with total scores ranging from 36 to 180. A higher score is reflective of less stress for the parents. (NCT00367835)
Timeframe: Baseline and up to 8 weeks

Intervention	Units on a scale (Mean)
SPD503	17.3
Placebo	7.2

Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)

CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00367835)
Timeframe: up to 8 weeks

Intervention	Participants (Number)
SPD503	93
Placebo	24

Number of Participants With Overall Satisfaction on the Medication Satisfaction Survey (MSS)

"The Medication Satisfaction Survey (MSS) consists of 11 questions each being answered with one of six responses (strongly agree, agree, somewhat agree, somewhat disagree, disagree, strongly disagree). Overall satisfaction with their child taking the study medication, Question #11, with a response of strongly agree or agree." (NCT00367835)
Timeframe: up to 8 weeks

Intervention	Participants (Number)
SPD503	84
Placebo	21

Assessment of Clinical Global Impression-Severity of Illness (CGI-S)

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00367835)
Timeframe: up to 8 weeks

Intervention	Participants (Number)
	1 (Normal, not at all ill)	2 (Borderline mentally ill)	3 (Mildly ill)	4 (Moderately ill)	5 (Markedly ill)	6 (Severely ill)	7 (Among the most extremely ill)
Placebo	3	6	15	24	22	5	0
SPD503	25	33	29	26	13	4	0

Reviews

1 review available for guanfacine and Attention Deficit and Disruptive Behavior Disorders

Article	Year
Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatric clinics of North America, 1998, Volume: 45, Issue:5 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Anxiety Disorders; Attention Defici	1998

Trials

3 trials available for guanfacine and Attention Deficit and Disruptive Behavior Disorders

Article	Year
Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology, 2014, Volume: 24, Issue:5 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit and Disruptive Behavior Disorder	2014
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS drugs, 2010, Volume: 24, Issue:9 Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit and Disruptive Behavior Disorders; Attention	2010
Increased plasma valproate concentrations when coadministered with guanfacine. Journal of child and adolescent psychopharmacology, 1998, Volume: 8, Issue:2 Topics: Adrenergic alpha-Agonists; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Att	1998

Other Studies

5 other studies available for guanfacine and Attention Deficit and Disruptive Behavior Disorders

Article	Year
Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. Journal of developmental and behavioral pediatrics : JDBP, 2020, Volume: 41, Issue:7 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit and Disruptive Behavior Disorder	2020
Paradoxical Hypertensive Urgency in a Child After Initiation of Guanfacine. Journal of child and adolescent psychopharmacology, 2017, Volume: 27, Issue:5 Topics: Antihypertensive Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Guanfacine; Hum	2017
Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. The Journal of clinical psychiatry, 2010, Volume: 71, Issue:3 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Attention Deficit and Disruptive Be	2010
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde Pharmacoepidemiology and drug safety, 2012, Volume: 21 Suppl 2 Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attentio	2012
Impaired visuospatial divided attention in the spontaneously hypertensive rat. Behavioural brain research, 2005, Feb-28, Volume: 157, Issue:2 Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Attention; Attention Deficit and Disruptiv	2005